Immune Therapeutics, Inc.

(IMUN) Bolsters
Board of Directors with Addition of Selsky
and Akin
Immune Therapeutics, Inc. (OTCQB: IMUN) made two additions to its board recently, and if
experience and knowledge are said to be key indicators of effectiveness, employees and
shareholders alike have reason to be elated with the news. Dr. Clifford A. Selsky and Paul Akin
carry a wealth of experience in their respective areas of influence and bolster the companys
leadership assets going forward. Paul Akin brings financial experience developed across his
prior operating and board roles to the IMUN board. Dr. Selsky offers a vital perspective as a
scientist, physician and patient advocate. The company intends to use their respective knowhow on its road toward pursuing financial growth while developing and commercializing novel,
Microcap Newsletter Ratings patented therapies for life-threatening diseases by activating the

bodys immune system.

Noreen Griffin, CEO of Immune Therapeutics, noted in a press release, Paul Akin and Dr.
Selskys breadth of knowledge and experience will provide invaluable insight to Immune as we
continue to grow the business and strive to deliver innovative therapies in emerging nations.
Clifford A. Selsky, PhD, MD, has been a pediatrician for the past 20 years, earning his PhD in
microbiology and molecular genetics at the University of Miami School of Medicine prior to
completing DNA repair research studies at Harvard School of Public Health and Stanford
University.
Paul Akin brings more than 25 years of leadership experience to IMUNs board. Akin played an
important role in the strategic planning and coordination of market penetration, capitalization
and expansion. He currently serves as the CEO and executive chairman of San Franciscobased Collier Warehouse Group, where hes fostered annual double-digit growth rates during
his tenure.
Immune Therapeutics, Inc. is a biotechnology company with a leading portfolio of
immunotherapy technologies aimed at capturing the promise of the immune system for
improving the treatment of cancer, HIV/Aids and other chronic and autoimmune diseases. The
company is currently looking into investigations of its programs for met-enkephalin (MENK) and

low dose naltrexone (LDN), Stock Newsletters or Lodonal as treatments for many
underserved indications.
In February, leading independent equity research and corporate access firm SeeThruEquity
announced that it has initiated coverage on Immune Therapeutics with a 12-month price target
of $0.61.